Protective effect of pioglitazone, a PPARγ ligand, in a 3 nitropropionic acid model of Huntington's disease

Maddalena Napolitano, Loredana Costa, Rocco Palermo, Alessandro Giovenco, Alessandra Vacca, Alberto Gulino

Research output: Contribution to journalArticle

Abstract

The peroxisome proliferator-activated receptor γ (PPARγ) is a member of the PPAR family. PPARγ is the target of insulin-sensitising thiazolidinediones (TZDs), drugs used for the treatment of non-insulin-dependent diabetes. Recently, several studies have shown that PPARγ activators can also prevent or attenuate neurodegeneration.The PPARγ agonist pioglitazone provides neuroprotection to dopaminergic neurons in lipopolysaccharide (LPS) and MPTP-induced Parkinson's disease experimental models.Here, we investigated whether PPARγ activation by pioglitazone protected striatal cells from mitochondrial dysfunction and oxidative stress in a 3 nitropropionic acid (3NP)-induced experimental model of Huntington's disease (HD).Our results suggested that pioglitazone has beneficial effects on mitochondrial dysfunction by interfering with the NF-κB signalling pathway, which has been implicated in the pathogenesis of HD.Additionally, we demonstrated that the nuclear translocation of HDAC3 is regulated by 3NP via IκBα and that treatment with pioglitazone prevented these effects.These results suggested that IκBα-dependent nuclear translocation is responsible for PPARγ inhibition by 3NP and pointed to histone modifications as a novel approach for treating HD.

Original languageEnglish
Pages (from-to)231-237
Number of pages7
JournalBrain Research Bulletin
Volume85
Issue number3-4
DOIs
Publication statusPublished - May 30 2011

Fingerprint

pioglitazone
Peroxisome Proliferator-Activated Receptors
Huntington Disease
Ligands
Theoretical Models
Histone Code
Corpus Striatum
Thiazolidinediones
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Dopaminergic Neurons
3-nitropropionic acid
Parkinson Disease
Lipopolysaccharides
Oxidative Stress

Keywords

  • Acetylation
  • Huntington's disease
  • NF-κB
  • NOS
  • Pioglitazone
  • PPARγ

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Protective effect of pioglitazone, a PPARγ ligand, in a 3 nitropropionic acid model of Huntington's disease. / Napolitano, Maddalena; Costa, Loredana; Palermo, Rocco; Giovenco, Alessandro; Vacca, Alessandra; Gulino, Alberto.

In: Brain Research Bulletin, Vol. 85, No. 3-4, 30.05.2011, p. 231-237.

Research output: Contribution to journalArticle

Napolitano, Maddalena ; Costa, Loredana ; Palermo, Rocco ; Giovenco, Alessandro ; Vacca, Alessandra ; Gulino, Alberto. / Protective effect of pioglitazone, a PPARγ ligand, in a 3 nitropropionic acid model of Huntington's disease. In: Brain Research Bulletin. 2011 ; Vol. 85, No. 3-4. pp. 231-237.
@article{5980da4958794a46bf31e72b2bcc485e,
title = "Protective effect of pioglitazone, a PPARγ ligand, in a 3 nitropropionic acid model of Huntington's disease",
abstract = "The peroxisome proliferator-activated receptor γ (PPARγ) is a member of the PPAR family. PPARγ is the target of insulin-sensitising thiazolidinediones (TZDs), drugs used for the treatment of non-insulin-dependent diabetes. Recently, several studies have shown that PPARγ activators can also prevent or attenuate neurodegeneration.The PPARγ agonist pioglitazone provides neuroprotection to dopaminergic neurons in lipopolysaccharide (LPS) and MPTP-induced Parkinson's disease experimental models.Here, we investigated whether PPARγ activation by pioglitazone protected striatal cells from mitochondrial dysfunction and oxidative stress in a 3 nitropropionic acid (3NP)-induced experimental model of Huntington's disease (HD).Our results suggested that pioglitazone has beneficial effects on mitochondrial dysfunction by interfering with the NF-κB signalling pathway, which has been implicated in the pathogenesis of HD.Additionally, we demonstrated that the nuclear translocation of HDAC3 is regulated by 3NP via IκBα and that treatment with pioglitazone prevented these effects.These results suggested that IκBα-dependent nuclear translocation is responsible for PPARγ inhibition by 3NP and pointed to histone modifications as a novel approach for treating HD.",
keywords = "Acetylation, Huntington's disease, NF-κB, NOS, Pioglitazone, PPARγ",
author = "Maddalena Napolitano and Loredana Costa and Rocco Palermo and Alessandro Giovenco and Alessandra Vacca and Alberto Gulino",
year = "2011",
month = "5",
day = "30",
doi = "10.1016/j.brainresbull.2011.03.011",
language = "English",
volume = "85",
pages = "231--237",
journal = "Brain Research Bulletin",
issn = "0361-9230",
publisher = "Elsevier Inc.",
number = "3-4",

}

TY - JOUR

T1 - Protective effect of pioglitazone, a PPARγ ligand, in a 3 nitropropionic acid model of Huntington's disease

AU - Napolitano, Maddalena

AU - Costa, Loredana

AU - Palermo, Rocco

AU - Giovenco, Alessandro

AU - Vacca, Alessandra

AU - Gulino, Alberto

PY - 2011/5/30

Y1 - 2011/5/30

N2 - The peroxisome proliferator-activated receptor γ (PPARγ) is a member of the PPAR family. PPARγ is the target of insulin-sensitising thiazolidinediones (TZDs), drugs used for the treatment of non-insulin-dependent diabetes. Recently, several studies have shown that PPARγ activators can also prevent or attenuate neurodegeneration.The PPARγ agonist pioglitazone provides neuroprotection to dopaminergic neurons in lipopolysaccharide (LPS) and MPTP-induced Parkinson's disease experimental models.Here, we investigated whether PPARγ activation by pioglitazone protected striatal cells from mitochondrial dysfunction and oxidative stress in a 3 nitropropionic acid (3NP)-induced experimental model of Huntington's disease (HD).Our results suggested that pioglitazone has beneficial effects on mitochondrial dysfunction by interfering with the NF-κB signalling pathway, which has been implicated in the pathogenesis of HD.Additionally, we demonstrated that the nuclear translocation of HDAC3 is regulated by 3NP via IκBα and that treatment with pioglitazone prevented these effects.These results suggested that IκBα-dependent nuclear translocation is responsible for PPARγ inhibition by 3NP and pointed to histone modifications as a novel approach for treating HD.

AB - The peroxisome proliferator-activated receptor γ (PPARγ) is a member of the PPAR family. PPARγ is the target of insulin-sensitising thiazolidinediones (TZDs), drugs used for the treatment of non-insulin-dependent diabetes. Recently, several studies have shown that PPARγ activators can also prevent or attenuate neurodegeneration.The PPARγ agonist pioglitazone provides neuroprotection to dopaminergic neurons in lipopolysaccharide (LPS) and MPTP-induced Parkinson's disease experimental models.Here, we investigated whether PPARγ activation by pioglitazone protected striatal cells from mitochondrial dysfunction and oxidative stress in a 3 nitropropionic acid (3NP)-induced experimental model of Huntington's disease (HD).Our results suggested that pioglitazone has beneficial effects on mitochondrial dysfunction by interfering with the NF-κB signalling pathway, which has been implicated in the pathogenesis of HD.Additionally, we demonstrated that the nuclear translocation of HDAC3 is regulated by 3NP via IκBα and that treatment with pioglitazone prevented these effects.These results suggested that IκBα-dependent nuclear translocation is responsible for PPARγ inhibition by 3NP and pointed to histone modifications as a novel approach for treating HD.

KW - Acetylation

KW - Huntington's disease

KW - NF-κB

KW - NOS

KW - Pioglitazone

KW - PPARγ

UR - http://www.scopus.com/inward/record.url?scp=79957858160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957858160&partnerID=8YFLogxK

U2 - 10.1016/j.brainresbull.2011.03.011

DO - 10.1016/j.brainresbull.2011.03.011

M3 - Article

C2 - 21440606

AN - SCOPUS:79957858160

VL - 85

SP - 231

EP - 237

JO - Brain Research Bulletin

JF - Brain Research Bulletin

SN - 0361-9230

IS - 3-4

ER -